Stopping Wegovy or Zepbound: What the Trial Data Actually Shows About the Rebound

The first thing people notice isn't hunger. It's the noise.

Around three to six weeks after the last shot of semaglutide or tirzepatide, the chatter comes back. What's in the fridge. What's for lunch. What you'd eat if nobody was watching. On r/Zepbound and r/Ozempic people keep reaching for the same metaphor: the volume knob turning back up. Ghrelin, the hunger hormone GLP-1 drugs suppress, returns to pre-treatment levels inside about 4 to 8 weeks. Leptin sensitivity and resting energy expenditure, both of which slid during weight loss, take longer to recover, if they recover at all.

That gap is the whole story. The drug leaves. The biology it was masking doesn't.

Week 1 to month 12: what the curve looks like

Semaglutide has a half-life of roughly 7 days. Tirzepatide sits near 5 days. Liraglutide clears in about 13 hours, which is why Saxenda is a daily shot. Functionally, most people are "off" the weekly drugs around 5 to 6 weeks after their last injection.

Here is the typical arc, drawn from STEP and SURMOUNT extension data plus U.S. claims patterns.

Not everyone follows this curve. Roughly 20 to 30% of people hold a meaningful share of their loss at a year. More on who they are below.

Why the rebound hits this hard

GLP-1 receptor agonists don't only dampen appetite. They slow gastric emptying, push satiety signals from the gut to the hypothalamus, and at higher doses look like they recalibrate reward processing around food. Remove the drug and you aren't returning to a neutral baseline. You're returning to a body that just spent 68 weeks at a lower weight, with adaptive thermogenesis still running in the background.

Adaptive thermogenesis is why bariatric surgery patients and the Biggest Loser cohort show the same shape: resting metabolic rate falls more than body-size math predicts, and it stays down. The 2016 Fothergill paper found Biggest Loser contestants were still running about 500 kcal/day below predicted REE six years after the finale. GLP-1 discontinuation drops people into the same physiology. Hungrier, with a quieter furnace.

The drug isn't building a new setpoint. It's holding the old one down. When you stop, the old setpoint is still sitting there, waiting.

Ghrelin rebound, return of food-reward signaling, depressed REE. Three forces, same direction.

What the withdrawal trials really show

Three studies carry the evidence. Read them, not the headlines about them.

STEP-1 extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022). The original STEP-1 ran semaglutide 2.4 mg for 68 weeks and produced a mean body-weight change of −17.3%. In the extension, 327 participants stopped both the drug and the lifestyle program. Over the next 52 weeks off-treatment they regained about two-thirds of the loss. Net change at week 120 versus baseline: roughly −5.6%. Blood pressure, HbA1c, and lipid improvements partially reversed on the same clock.

STEP-4 (Rubino et al., JAMA, 2021). After a 20-week run-in on semaglutide 2.4 mg, participants were randomized to continue or switch to placebo. The continue arm lost another 7.9% by week 68. The placebo arm gained 6.9%. Same people, same starting weight, one variable.

SURMOUNT-4 (Aronne et al., JAMA, 2024). The tirzepatide version. After a 36-week lead-in at the maximum tolerated dose (mean loss −20.9%), participants were randomized. The continue arm lost another 5.5% over 52 weeks. The placebo arm gained 14%, wiping out most of the lead-in.

One honest reading: stopping erases most of the benefit inside a year. Another honest reading: even after regain, participants still ended up below their starting weight. Both are true. Which one matters to you depends on why you started.

For the underlying labels, the Wegovy prescribing information and the Zepbound prescribing information say nothing about how to come off, because the trials didn't test a taper.

The cardiovascular benefit is conditional

The SELECT trial (Lincoff et al., NEJM, 2023) is why Wegovy carries an FDA indication for cardiovascular risk reduction. In 17,604 adults with established cardiovascular disease and overweight or obesity, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over a mean follow-up of 39.8 months.

The analysis is intention-to-treat. People who stopped were still counted in the treatment arm, so we don't have clean data on what the 20% relative risk reduction looks like after discontinuation. Mechanistically, most of the MACE benefit tracks sustained weight loss, lower blood pressure, and better inflammatory markers. All of those fade when the drug stops.

If you're on Wegovy primarily for cardiovascular protection after a heart attack or stroke, stopping is a different calculation than stopping for weight management. That conversation belongs with your cardiologist, not a 15-minute PCP slot.

The U.S. access cliff, April 2026

A lot of the people coming off GLP-1s in the U.S. right now aren't stopping because of trial data. They're stopping because the math moved.

Four things shifted between December 2025 and April 2026:

1. Oral Wegovy launched. The FDA approved semaglutide 25 mg oral for obesity in December 2025, and Novo launched in January 2026. First-quarter starts cleared 400,000, which says injection aversion was a bigger drag on adherence than anyone admitted.
2. Foundayo (orforglipron) got approved April 1, 2026. Lilly's oral small-molecule GLP-1. No food restrictions, priced at about $149/month cash. Efficacy sits below tirzepatide in head-to-head pipeline reads, but it is a real pathway for people who can't swing injectable cost or can't tolerate them.
3. Medicare GLP-1 Bridge starts July 1, 2026. Qualifying Medicare beneficiaries get Wegovy or Zepbound at $50/month. About 67 million people are eligible in principle. This is the single largest coverage expansion in the history of anti-obesity medication.
4. The FDA compounding enforcement window closes April to May 2026. 503A and 503B pharmacies that built businesses on compounded semaglutide during the 2022 to 2024 shortage are exiting. People who were paying $199 a month for compounded tirz or sema are getting non-renewal letters right now.

PBM claims data keeps showing the same thing: 30 to 50% of people starting Wegovy or Zepbound stop inside 12 months, and cost is the top-cited reason. Above side effects. Above plateau. Above everything. A large share of U.S. "discontinuation" isn't a medical decision. It's a budget decision.

Taper or cold turkey

There is no official taper protocol. Neither Wegovy nor Zepbound labeling tells you how to step down, because the trials stopped the drug abruptly. That is partly why the regain curves look as steep as they do.

What obesity medicine doctors actually do varies, but the common pattern:

• Drop one dose level every 4 to 8 weeks. For Wegovy: 2.4 → 1.7 → 1.0 → 0.5 → 0.25 mg. For Zepbound: 15 → 12.5 → 10 → 7.5 → 5 → 2.5 mg.
• Hold at the lowest tolerated dose if insurance and cash allow. Some people maintain most of their loss at 1.0 mg semaglutide or 5 mg tirzepatide.
• If you're stopping entirely, get the behavioral scaffolding in place first, not after: protein target, resistance training, sleep, weigh-in cadence.

The better question for most people isn't "how do I stop." It's "can I get to a maintenance dose instead of zero." Most of the published regain data is binary, on or off. The maintenance-dose experience is under-studied but anecdotally different.

Protein intake of 1.2 to 1.6 g/kg/day with resistance training 2 to 3 times per week reduces lean-mass loss during therapy and improves metabolic resilience after. It's the highest-leverage behavioral lever we have data for, and it is almost never covered in a 15-minute visit.

The 20 to 30% who hold their loss

Across STEP and SURMOUNT extension cohorts, a minority held more than 5% weight loss at 12 months post-drug. The pattern is consistent enough to copy:

• Clinician follow-up every 4 to 12 weeks. Not "call if something's wrong."
• Weight tracked weekly. Small regains caught fast, not discovered three months later.
• Protein explicitly targeted. Not assumed.
• Resistance training twice a week or more, preserved through the taper.
• Sleep above 7 hours. Sleep loss pushes ghrelin up on its own.
• A pre-existing relationship with food. Not a diet. A pattern they can keep.

Nothing on that list is surprising. None of it is reliably delivered by a standard PCP visit either.

Questions to bring to your doctor

Specific, not generic. The appointment is 15 minutes. Use them.

• What am I actually treating, weight, cardiovascular risk, T2D control, and which one is driving this decision?
• Can I taper instead of stop, and what's the lowest dose my plan will keep covering?
• If I stop, what's the follow-up cadence for the first 6 months?
• What's my protein target in grams per day, and what's my resistance training baseline?
• Should I get a DEXA or BIA scan before stopping so I know my lean mass?
• If I'm on Wegovy for SELECT-indicated CV protection, does stopping change my risk calculus?
• What would make you suggest restarting, a specific weight, a specific lab, a specific symptom?

Before a new prescription or refill

Whether you're stopping, tapering, or refilling, these deserve a minute before you click buy.

• FDA indication match. Wegovy and Zepbound are approved for obesity (BMI ≥ 30, or ≥ 27 with a weight-related condition). Zepbound added moderate-to-severe OSA in 2024. Foundayo got obesity approval April 1, 2026.
• Insurance coverage and PA status. If you're moving from compounded to branded because of the enforcement window, your PA likely needs to be re-filed.
• 12-month cost projection. Not next month's copay. What happens if you hit the deductible reset in January.
• Pharmacy legitimacy. If it's compounded, confirm 503A or 503B registration and ask for the COA. After April to May 2026, most compounded GLP-1 for weight loss is outside FDA enforcement discretion.
• Refill logistics. Mail order versus retail, cold-chain shipping, vacation hold policies.
• Baseline labs. HbA1c, lipid panel, kidney function, a dated weight.
• Contraindications. Personal or family history of medullary thyroid carcinoma or MEN 2. Active gallbladder disease. Severe gastroparesis.

U.S. market reality, April 2026

The 2026 U.S. market is less a story about molecules and more a story about who gets to stay on them. The drugs work. The system around them is what people navigate in real life.

A few things to hold in your head:

• Wegovy's oral form launched in January 2026 at the 25 mg oral dose, after the December 2025 FDA approval. More than 400,000 starts in the first quarter says injection aversion was a bigger barrier than most prescribers modeled.
• Zepbound vials via LillyDirect at $349 to $499 are the cash-pay floor for tirzepatide. The vial is less convenient than the pen, but the price gap is the difference between staying on and stopping for a lot of people.
• Foundayo at $149/month changes the cash-pay conversation entirely. It isn't tirzepatide-level in pipeline head-to-head efficacy, but it is an oral, food-restriction-free path for people shut out of injectables.
• Zepbound vs Mounjaro is the same molecule, different label. Mounjaro got T2D approval in May 2022. Zepbound got obesity approval in November 2023. Insurers use the labels to decide coverage even though your pharmacist is dispensing the same tirzepatide.
• Medicare GLP-1 Bridge in July 2026 is the biggest structural shift. If you or a family member are Medicare-eligible, the math in October 2026 looks different from the math in April 2026. Don't lock in a decision now that you'd regret in three months.
• Commercial coverage is tightening, not loosening. PBM formularies are adding prior-failure requirements, usually phentermine or metformin first. Appeals work, but they cost time and paperwork.

One practical read. If cost is pushing you to stop, talk to your prescriber about a cheaper bridge before you stop, Foundayo, a lower maintenance dose, LillyDirect vials, or waiting out the Medicare Bridge if you qualify. The regain curve is faster than the paperwork.

If side effects are pushing you to stop, the conversation is different. Dose reduction, antiemetics, slower titration, or switching molecules. Worth raising before you skip the next dose on your own.

The short version

Stopping a GLP-1 isn't like stopping an antibiotic. Hunger comes back in weeks. Weight comes back in months. The cardiometabolic benefits are conditional on continued use. Two-thirds regained inside a year is the base rate, not a worst case.

That doesn't mean you can't stop. It means stopping is a decision that rewards a plan. A taper, a protein target, a training baseline, a follow-up cadence, and a written answer to "what would make me restart." The people who hold their loss at 12 months aren't the ones with more willpower. They're the ones with more scaffolding.

If you're reading this because you're thinking about stopping, the most useful next step isn't stopping. It is writing down your goal, your budget, and your follow-up plan, and taking all three to the next appointment.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app